@misc{oai:repo.qst.go.jp:00077442,
 author = {趙, 松吉 and 吉永, 恵一郎 and 粟生木, 美穂 and 右近, 直之 and 下山, 彩希 and 西嶋, 剣一 and 鷲山, 幸信 and 鷲野, 弘明 and 高橋, 和弘 and 東, 達也 and 伊藤, 浩 and Zhao, Songji and Yoshinaga, Keiichiro and Aoki, Miho and Ukon, Naoyuki and Nishijima, Kenichi and Koushin, Washiyama and Washino, Komei and Higashi, Tatsuya and Ito, Hiroshi},
 month = {Nov},
 note = {The alpha-emitting radiopharmaceutical meta-[211At]astatobenzylguanidine (211At-MABG) has potential as a metastatic pheochromocytoma treatment. As 211At-MABG does not emit gamma-rays suitable for dosimetry and imaging, 211At-MABG needs a companion diagnostic imaging agent such as meta-[123I]iodobenzylguanidine (123I-MIBG) to be used in making treatment decisions. We evaluated the similarities and differences between 123I-MIBG and 211At-MABG in biodistribution in normal mice. BALB/c mice were injected with 123I-MIBG or 211At-MABG, and the radioactivity levels (%ID/g) in the tissues were determined at 1 and 30 min, and 1, 3, 6, and 24 h after the injection.
Results: 211At-MABG and 123I-MIBG showed very similar biodistribution profiles in normal mice at every time point. 
Conclusions: 123I-MIBG can be used for dosimetry and imaging for decisions regarding treatment with 211At-MABG radiotherapy., 第59回日本核医学会学術総会},
 title = {正常マウスにおける123I-MIBGと211At-MABGの体内動態の評価},
 year = {2019}
}